Back

Watch Compare

Seres Therapeutics, Inc.

Data quality: 100%

MCRB

Nasdaq Manufacturing Chemicals

$8.87

▲ $0.11 (1.20%)

Mkt Cap: 84.98 M

Price

$8.87

Mkt Cap

84.98 M

Day Range

$8.58 — $9.18

52-Week Range

$6.53 — $29.98

Volume

8,303

Open $8.91

50D / 200D Avg

$10.48

15.40% below

50D / 200D Avg

$14.74

39.88% below

Quick Summary

Key Takeaways

Revenue declined -72.84% annually over 5 years

Earnings grew 4088.24% over the past year

ROE of 14.86% — decent returns on equity

Net margin of 721.93% shows strong profitability

Generating 865,000.0 in free cash flow

P/E of 14.92 — trading at a low valuation

Growth

Revenue Growth (5Y)

-72.84%

Below sector avg (1.82%)

Revenue (1Y)N/A

Earnings (1Y)4088.24%

FCF Growth (3Y)N/A

Quality

Return on Equity

14.86%

Above sector avg (-53.47%)

ROIC-63.48%

Net Margin721.93%

Op. Margin-11910.14%

Safety

Debt / Equity

N/A

Current Ratio2.30

Interest CoverageN/A

Valuation

PE (TTM)

14.92

Above sector avg (-1.47)

P/B Ratio1.94

EV/EBITDAN/A

Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)

Metric	Stock	Sector Median
P/E	14.9	-1.5
P/B	1.9	1.6
ROE %	14.9	-53.5
Net Margin %	721.9	-41.5
Rev Growth 5Y %	-72.8	1.8
D/E	—	0.3

ETFs Holding This Stock

BRSIX BRSIX

0.18% weight

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	-92.10%
Earnings Growth (1Y)	4088.24%	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	-72.84%	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	789,000.0	Net Income (TTM)	5.70 M
ROE	14.86%	ROA	3.97%
Gross Margin	N/A	Operating Margin	-11910.14%
Net Margin	721.93%	Free Cash Flow (TTM)	865,000.0
ROIC	-63.48%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	2.30
Interest Coverage	N/A	Asset Turnover	0.01
Working Capital	29.10 M	Tangible Book Value	43.70 M
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	14.92	Forward P/E	N/A
P/B Ratio	1.94	P/S Ratio	107.71
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	1.02%
Market Cap	84.98 M	Enterprise Value	37.34 M
Per Share
EPS (Diluted TTM)	0.64	Revenue / Share	0.08
FCF / Share	0.09	OCF / Share	0.12
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	31.94%	FCF Conversion	15.19%
SBC-Adj. FCF	-11.96 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	789,000.0	—	126.33 M	7.13 M	144.93 M
Net Income	5.70 M	136,000.0	-113.72 M	-250.16 M	-65.58 M
EPS (Diluted)	0.64	0.00	-0.89	-2.31	—
Gross Profit	—	—	—	—	—
Operating Income	-93.97 M	-121.32 M	-107.98 M	-246.49 M	-64.49 M
EBITDA	—	—	—	—	—
R&D Expenses	49.06 M	64.60 M	145.86 M	172.92 M	141.89 M
SG&A Expenses	—	—	—	—	—
D&A	4.13 M	5.47 M	6.24 M	6.63 M	5.95 M
Interest Expense	0.0	0.0	13.18 M	6.02 M	2.91 M
Income Tax	0.0	0.0	0.0	0.0	0.0

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	138.19 M	139.81 M	358.60 M	348.78 M	354.86 M
Total Liabilities	93.98 M	126.03 M	403.46 M	338.00 M	223.35 M
Shareholders' Equity	44.22 M	13.78 M	-44.86 M	10.78 M	131.51 M
Total Debt	—	—	110.00 M	50.00 M	24.05 M
Cash & Equivalents	45.77 M	30.79 M	127.97 M	163.03 M	180.00 M
Current Assets	49.38 M	38.67 M	175.41 M	194.76 M	303.63 M
Current Liabilities	19.32 M	41.22 M	98.66 M	85.60 M	82.26 M